Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iC9.CAR-CSPG4 T cells in recurrent/metastatic HNSCC
NCT06096038Phase 1Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Apr 2024
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iC9-CAR.CSPG4 T cells in head and neck squamous cell carcinoma (HNSCC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Toxicity: NCI-CTCAE at 4 weeks, Cytokine Release Syndrome at 4 weeks and 3 more. Started Apr 2024; status: recruiting.
02
Drugs
iC9-CAR.CSPG4 T cells
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06096038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06096038.